Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Roswell Park Cancer Institute
University of Alabama at Birmingham
NantCell, Inc.
ImmunityBio, Inc.
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC
Pfizer
Nektar Therapeutics
Xennials Therapeutics Australia Pty Ltd
Eisai Inc.
PharmaEngine
National Cancer Institute (NCI)
ASLAN Pharmaceuticals
Regeneron Pharmaceuticals
Mereo BioPharma
Louisiana State University Health Sciences Center Shreveport
Shanghai Proton and Heavy Ion Center
Celgene
University Health Network, Toronto
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
National Cancer Center, Korea
Vanderbilt-Ingram Cancer Center
Eisai Inc.
Hoosier Cancer Research Network
Dana-Farber Cancer Institute
Duke University
Centre Hospitalier Universitaire Vaudois
University of Tennessee Cancer Institute
Nevada Cancer Institute
Case Comprehensive Cancer Center
Eli Lilly and Company
Weill Medical College of Cornell University